Skip to main content

Table 2 Demographic data of the patients with AD at baseline by disease severity

From: The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease

  CDR = 0.5
(n = 20)
CDR = 1.0
(n = 208)
CDR = 2.0
(n = 81)
CDR = 3.0
(n = 12)
P value*
Male patients, n (%) 13 (65.0%) 104 (50.0%) 49 (60.5%) 7 (58.3%) 0.29
Age (years) 79.2 (5.4) 80.3 (6.0) 80.6 (6.7) 82.5 (7.7) 0.49
Education (years) 9.6 (4.9) 10.2 (4.5) 9.7 (4.3) 12.4 (3.6) 0.22
Disease duration (months) 24.8 (16.7) 51.1 (48.6) 56.4 (39.7) 99.3 (71.6) < 0.01
BMI (kg/m2) 24.5 (3.4) 23.6 (3.2) 23.9 (3.5) 20.3 (3.1) 0.03
MMSE 22.8 (2.9) 19.9 (4.2) 14.2 (5.0) 3.7 (3.5) < 0.01
NPI-agitation/aggression 5.5 (13.3) 5.5 (10.0) 10.1 (13.5) 14.8 (22.1) < 0.01
NPI-mood 6.3 (12.9) 4.7 (8.6) 6.5 (8.8) 9.8 (16.2) 0.15
NPI-frontal 5.1 (10.1) 4.6 (8.9) 8.0 (10.5) 11.3 (19.5) 0.01
ApoE4 carrier 6 (30%) 77 (37.0%) 44 (54.3%) 7 (58.3%) < 0.01
Plasma clusterin level (μg/ml) 253.6 (36.9) 244.9 (36.6) 255.9 (40.9) 252.7 (38.9) 0.15
Aβ1–40 (pg/ml) 144.7 (28.7) 160.4 (47.8) 154.7 (55.5) 162.8 (87.2) 0.51
Aβ1–42 (pg/ml) 38.9 (11.9) 34.1 (13.9) 33.6 (15.6) 57.4 (87.4) < 0.01
Ratio of Aβ1–42/Aβ1–40 (%) 26.9 (5.7) 21.8 (9.2) 22.5 (10.8) 28.3 (17.8) 0.08
  1. Values are means with standard deviations unless otherwise indicated
  2. *ANOVA or Kruskal-Wallis tests
  3. amyloid beta, AD Alzheimer’s disease, ApoE apolipoprotein E, BMI body mass index, CDR Clinical Dementia Rating, MMSE Mini-Mental State Examination, NPI Neuropsychiatric Inventory